Illumina, Inc.

Global $5+ Billion Nucleic Acid Isolation and Purification Market Analysis and Forecast Research Report 2021-2031 - ResearchAndMarkets.com

Wednesday, August 4, 2021 - 2:42pm

The "Global Nucleic Acid Isolation and Purification Market: Focus on Product, End User, Region/Country Data and Competitive Landscape - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nucleic Acid Isolation and Purification Market: Focus on Product, End User, Region/Country Data and Competitive Landscape - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • The report found the nucleic acid isolation and purification market to be one of the growing markets, which is predicted to grow at a CAGR of 7.20% during the forecast period, 2021-2031.
  • Within the research report, the market is segmented on the basis of product type, end users, and region.
  • The nucleic acid isolation and purification market has immensely propelled by nationwide sequencing activities, focusing on generating large genomic libraries for research and development purpose.

Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India

Wednesday, August 4, 2021 - 2:30am

SAN DIEGO, Aug. 3, 2021 /PRNewswire/ --Illumina, Inc. (NASDAQ: ILMN) has donated $1 million in sequencing capabilities to the Molecular Diagnostic Reference Laboratory at Kasturba Hospital, in the Municipal Corporate of Greater Mumbai, to helpexpand SARS-CoV-2 sequencing capabilitiesin the region and support the broader genomic surveillance effort across India.

Key Points: 
  • SAN DIEGO, Aug. 3, 2021 /PRNewswire/ --Illumina, Inc. (NASDAQ: ILMN) has donated $1 million in sequencing capabilities to the Molecular Diagnostic Reference Laboratory at Kasturba Hospital, in the Municipal Corporate of Greater Mumbai, to helpexpand SARS-CoV-2 sequencing capabilitiesin the region and support the broader genomic surveillance effort across India.
  • Kasturba Hospital was the first hospital in Mumbai to begin sequencing SARS-CoV-2 this year and will examine how variants of the virus are being spread across India.
  • "Illumina believes in democratization of access to sequencing and we are committed to helping the regions of the world that carry most of the infectious disease burden to build genomics capabilities," said Francis deSouza, Chief Executive Officer of Illumina.
  • "This donation will help to make NGS technology and expertise accessible in Mumbai, supporting the region and contributing to genomic surveillance in India more broadly."

Illumina to Webcast Upcoming Investor Conference

Wednesday, July 28, 2021 - 11:30pm

Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:

Key Points: 
  • Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
    UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021
    The live webcast can be accessed under the Investor Info section of the "company" tab at www.illumina.com .
  • A replay will be posted on Illuminas website after the event and will be available for at least 30 days following.
  • Illumina is improving human health by unlocking the power of the genome.
  • Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase

Thursday, July 22, 2021 - 5:49pm

We look forward to presenting our position during the Phase II process, said Charles Dadswell, General Counsel for Illumina.

Key Points: 
  • We look forward to presenting our position during the Phase II process, said Charles Dadswell, General Counsel for Illumina.
  • Illumina is also challenging the ECs jurisdiction to investigate the transaction under Article 22 of the European Union (EU) Merger Regulation.
  • Illumina has filed an action in the General Court of the EU seeking annulment of the ECs jurisdiction to review the acquisition.
  • Illuminas re-acquisition of GRAIL means that millions of citizens across the European Economic Area (EEA) will be able to access life-saving early cancer screening years sooner.

Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated precision medicine strategy

Monday, July 19, 2021 - 12:07pm

Dante Labs integrated precision medicine offering leverages the intersection of local lab operations with centralised software and database.

Key Points: 
  • Dante Labs integrated precision medicine offering leverages the intersection of local lab operations with centralised software and database.
  • CAMBRIDGE, United Kingdom, July 19, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, announced today the appointment of Bob Ragusa as a board member.
  • Dante Labs CEO Andrea Riposati stated, As Illumina customers, we have been amazed by Illuminas global customer support and operational excellence.
  • Bob is a life science rockstar and will help us deploy our global commercial and clinical offering for multi-omics and integrated precision medicine.

Sanigen announces partnership with Illumina on Food safety and Microbiology Business Development in South Korea

Wednesday, July 14, 2021 - 5:00pm

The partners will work together to deliver Illumina's NGS platform technology to the food safety and microbiology sector in South Korea.

Key Points: 
  • The partners will work together to deliver Illumina's NGS platform technology to the food safety and microbiology sector in South Korea.
  • Sanigen is a specialist food safety company in South Korea and serves the market with PCR kits and NGS panels.
  • Sanigen, together with Illumina, is developing NGS panels that can rapidly detect 16 types of foodborne pathogen from around 400 samples.
  • The companies believe that the partnership will accelerate the application of NGS technology to the food safety market, improving safety levels.

Sanigen announces partnership with Illumina on Food safety and Microbiology Business Development in South Korea

Wednesday, July 14, 2021 - 8:00am

The partners will work together to deliver Illumina's NGS platform technology to the food safety and microbiology sector in South Korea.

Key Points: 
  • The partners will work together to deliver Illumina's NGS platform technology to the food safety and microbiology sector in South Korea.
  • Sanigen is a specialist food safety company in South Korea and serves the market with PCR kits and NGS panels.
  • Sanigen, together with Illumina, is developing NGS panels that can rapidly detect 16 types of foodborne pathogen from around 400 samples.
  • The companies believe that the partnership will accelerate the application of NGS technology to the food safety market, improving safety levels.

Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Tuesday, July 13, 2021 - 10:00pm

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2021 following the close of market on Thursday, August 5, 2021.

Key Points: 
  • Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2021 following the close of market on Thursday, August 5, 2021.
  • The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, August 5, 2021.
  • Interested parties may access the live teleconference through the Investor Info section of Illuminas website under the company tab at www.illumina.com .
  • Alternatively, individuals can access the call by dialing 1 (866) 211-4597 or 1 (647) 689-6853 outside North America, both with Conference ID 2850779.

SOPHiA DDM(TM) for TSO500 Furthers Analytical Capabilities

Thursday, July 1, 2021 - 1:00pm

The new data-to-report workflow is designed to maximize the utility of the Illumina TSO500 assay by optimizing its data output for secondary analysis.

Key Points: 
  • The new data-to-report workflow is designed to maximize the utility of the Illumina TSO500 assay by optimizing its data output for secondary analysis.
  • SOPHiA DDMTM for TSO500 offers an accelerated assessment of genomic data thanks to variant pre-classification that is supported by advanced algorithms, customizable filters and hotspot screening.
  • Expanding the scope of a test may traditionally come with complexities, but SOPHiA GENETICS simplifies the workflow while expanding detection abilities -- without sacrificing analytical capabilities.
  • Companion diagnostics can be quickly evaluated and deployed leveraging Protean's extensive laboratory capabilities, expertise, and extensive global research networks.

Felix Biotechnology announces initiation of research collaboration with Biocogent, the leading provider of high technology products to personal care and cosmetic industries.

Monday, June 28, 2021 - 1:00pm

Felix Biotechnology to develop novel chemical free and targeted ingredients for Biocogent skin care applications.

Key Points: 
  • Felix Biotechnology to develop novel chemical free and targeted ingredients for Biocogent skin care applications.
  • Biocogent, LLC is a leading provider of high technology products and services to the personal care and cosmetic industries.
  • Biocogent utilizes pioneering technology in research, development, and manufacturing to provide innovative value-driven functional ingredients and services to its customers.
  • Felix is a seed stage company funded by multiple investors, including Y Combinator, Illumina Accelerator and Point72 Ventures.